Core Viewpoint - Meinian Health has reported strong growth in its AI-driven healthcare services, with Q1 2025 revenue reaching 1.754 billion yuan, including over 54 million yuan from AI technology, marking a 71.76% increase year-on-year, indicating a significant shift from technological exploration to large-scale application in the "AI + healthcare" model [1] Group 1: AI Empowerment in Health Management - Meinian Health's core strategy revolves around "AI + healthcare," transforming the entire health check process into an intelligent service system, covering pre-examination, examination, and post-examination stages [1] - In the pre-examination phase, AI technology customizes health check packages based on individual and group client data, ensuring precision and relevance in health assessments [2] - During the examination, the company has implemented intelligent management tools that enhance customer experience and facilitate seamless transitions from routine screenings to precise diagnostics [2] - Post-examination services leverage AI systems like "Health Xiaomei" to provide personalized health management, with significant improvements in report accuracy and processing efficiency [2] Group 2: Innovation and Competitive Advantage - Meinian Health focuses on building eight core disciplines, utilizing AI to create unique competitive barriers, particularly in ultrasound technology [3] - The company has introduced specialized AI products for various health management areas, enhancing screening efficiency and promoting systematic solutions for early detection [4] - Innovative screening models, such as the "CT One Scan Multiple Checks" system, integrate multiple assessments into a single examination, significantly improving efficiency [4] Group 3: Expansion of Post-Examination Market - The company is transitioning from traditional health check services to comprehensive lifecycle health management, activating deeper individual client needs through innovative operational strategies [5] - Meinian Health is enhancing customer engagement by providing a one-stop solution that includes health checks, specialized examinations, health management, and insurance [6] Group 4: Industry Impact and Future Outlook - Meinian Health is evolving from a health check service provider to an AI health management solution platform, establishing a dual engine for performance growth through specialized early screening products and intelligent health management [7] - The company aims to leverage AI technology to expand into trillion-level markets, focusing on senior health, health management, and data elements, positioning itself as a leader in the digital health management era [8]

体检行业触底回升，银发经济催化市场结构性扩容，公司龙头地位多维夯实，打造银发经济服务闭环。 随着人口老龄化加速、慢性病管理需求激增，叠加《"十四五"健康老龄化规划》政策红利释放，我国体 检行业迎来发展新周期。2012-2022年行业规模CAGR达15.06%，预计2030年将突破5,200亿元。公司依 托"参转控"模式实现区域资源高效整合，在行业集中度提升趋势下显现显著竞争优势。通过深度布局的 296座城市、576家实体服务网点网络，公司持续承接中小机构退出市场的份额转移，形成规模化发展优 势。在业务架构层面，聚焦老龄化市场需求，战略性布局脑睿佳、心脑血管早筛、肿瘤标志物检测等银 发刚需项目，构建"预防筛查-健康管理-医疗转介"全链条服务体系。2024年度累计完成2,512万人次体检 服务，通过高毛利检测项目的组合优化，实现客单价同比提升8.25%至672元。 渠道增量与数据资产协同发力，构建第二增长曲线。公司坚持"保质、增收、提效、降本"的主线，以医 疗导向和服务品质为核心，深入挖掘客户需求，通过多渠道营销拓展线上线下客户，持续优化客户结 构。通过"网格化下沉+生态化延伸"开辟新增长空间：线下渠道端，实施" ...

证券研究报告·公司点评报告·医疗服务 美年健康（002044） 2024 年报点评：AI 营收初具规模，19 家机 构参变控增厚业绩 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 10,894 | 10,702 | 11,587 | 12,432 | 13,339 | | 同比（%） | 26.44 | (1.76) | 8.27 | 7.29 | 7.30 | | 归母净利润（百万元） | 505.62 | 282.24 | 629.21 | 911.79 | 1,124.91 | | 同比（%） | 190.45 | (44.18) | 122.94 | 44.91 | 23.37 | | EPS-最新摊薄（元/股） | 0.13 | 0.07 | 0.16 | 0.23 | 0.29 | | P/E（现价&最新摊薄） | 41.03 | 73.50 | 32.97 | 22.75 | 18.44 | [T ...

事件： 4 月14 日晚，美年健康发布公告，拟通过发行股份的方式购买交易对方持有的衡阳美年84.00% 股权、宁德美年81.00%股权、烟台美年75.00%股权、烟台美年福田49.00%股权、武汉奥亚52.81%股 权、三明美年85.00%股权、肥城美年90.00%股权、南宁美元康69.86%股权、德州美年84.00%股权、安 溪美年72.90%股权、连江美年82.00%股权、沂水美年80.50% 股权、山东奥亚92.35%股权、厦门银城美 年 81.00%股权及控股子公司郑州美健47.37%少数股权、花都美年49.00%少数股权、安徽美欣42.46%少 数股权、淄博美年49.00%少数股权、吉林昌邑美年48.05% 少数股权。合计19 家体检机构，此次交易完 成后，上市公司将直接及间接持有包括衡阳美年在内的18 家体检机构100.00%及安溪美年90.00%股权。 由于标的公司的审计、评估工作尚未完成，本次交易的具体交易价格尚未确定。 盈利预测与估值：由于收购的机构经营业绩尚未审计，并表时间也尚不明确，暂不调整上市公司盈利预 测。公司2024-2026 年营业收入预期分别为105.99、116.14、127 ...